Great Information, Real Community, Better Living.
 Main Page
 Shoulder News
Feature Story
Shoulder Technology
Real Life Recoveries
 Education Center
 Shoulder  Hero™
Dr. Evan Flatow:
Innovating Shoulder Surgery
About Heroes
 Join the Discussion in  Our Forums
Shoulder1 Forums
Patient Stories
Shoulder Journals
Ask an Expert
Locate a Doctor
Reference Library
Video Library
 Bookmark Us
Search the Body1 Network
April 18, 2021  
SHOULDER NEWS: Feature Story

  • Print this Article
  • Email this Article
  • Links/Reprints
  • U.S. to Reassess Arthritis Drug Safety

    U.S. to Reassess Arthritis Drug Safety

    March 05, 2003

    WASHINGTON (AP) - Increasing reports of major side effects - cancer and liver failure - are spurring the government to reassess the safety of rheumatoid arthritis drugs that gave patients unprecedented hope when they began hitting the market four years ago.

    "These drugs have shown tremendous benefit, but they ... all have pros and cons," said Dr. Karen Weiss of the Food and Drug Administration.

    Of the 2 million rheumatoid arthritis sufferers, thousands try one of the four drugs each year. Tuesday, the FDA's scientific advisers began two days of debate over how big a risk each medication poses and whether stronger warnings or restrictions are needed.

    The consumer advocacy group Public Citizen is pushing for one of the medicines, Arava, to be banned. Reaction within FDA is mixed. An agency analysis posted on the FDA's Web site Tuesday recommends a ban - citing 54 U.S. cases of liver failure or damage and eight deaths linked to the drug.

    "People should not use this," said Public Citizen's Dr. Sidney Wolfe, who contends Arava is far riskier than an equally effective, older alternative.

    Higher-ranking FDA officials will tell agency advisers Wednesday that they disagree, citing additional analyses that argue there's no proof Arava is more dangerous than competing treatments.

    "There are cases of liver injury that are possibly or probably related to use of Arava, but we also think it continues to have a place," said FDA drug chief Dr. John Jenkins. He said the FDA might find, however, that more safety restrictions were needed.

    The FDA also is struggling to determine if three other medicines - Enbrel, Remicade and Humira - are linked to 170 cases of lymphoma, a hard-to-treat immune system cancer, reported since 1998.

    Late Tuesday, FDA's advisers said the lymphoma reports signal a possible problem that should be monitored and explained on those drugs' labels. But they cautioned that it may take several more years to determine if there's truly a risk.

    Manufacturers argue patients already are adequately warned about all possible side effects, and there's no proof the drugs are to blame.

    "Causality is not easy to determine," said Dr. Francois Nader of Aventis Pharmaceuticals, Arava's maker. Meanwhile, "the physicians need choices, and the patients need choices."

    Rheumatoid arthritis, which affects mostly women, is not the wear-and-tear joint damage that plagues the elderly. Instead, the immune system goes awry and attacks patients' own cartilage, causing pain and swelling and eventually destroying the joint. It typically strikes between ages 25 and 50, and within 10 years about half of patients are too disabled to work.

    Standard treatment is a cancer drug called methotrexate. For years, few options existed for patients who failed methotrexate or couldn't tolerate its side effects, including liver damage.

    In 1998, new-generation treatments started selling. First came Arava, a chemical that blocks the overproduction of immune cells that inflame joints, similar to how methotrexate works.

    Then came Enbrel and Remicade, biologically engineered drugs that sop up a different inflammation-causing protein, tumor necrosis factor or TNF. A third TNF inhibitor, Humira, won FDA approval last December.

    From the start, FDA warned of serious risks. It urged doctors to check Arava patients regularly for liver damage, and stressed use of birth control because Arava could cause birth defects. All three TNF inhibitors carry warnings that they suppress the immune system enough to cause severe, even deadly, infections and theoretically could increase the risk of cancer.

    Now, after four years of sales, the FDA has reports of 170 cases of lymphoma among users of the three TNF inhibitors.

    It's hard to prove if the drugs play any role, Weiss cautioned. Rheumatoid arthritis itself increases lymphoma risk - RA patients get that cancer at two- to threefold higher rates than the general population. Plus, only 29 of the cases occurred during formal studies that allow full investigation.

    "You can make a case that the incidence of lymphomas is in the range you would expect to see in rheumatoid arthritis," said Tom Schaible of Centocor Inc., Remicade's maker.

    Dr. John Klippel of the Arthritis Foundation hopes the FDA meeting will help doctors and patients better compare each drug's different risks before choosing one. "These remain very important drugs," he said.

    Last updated: 05-Mar-03


  • Add Comment
    Interact on Shoulder1

    Discuss this topic with others.
    Feature Archives

    Surgery A Treatment Option For Young Patients With Shoulder Injuries

    Recommendations For Tablet Computer Use To Avoid Shoulder Pain

    3-D Motion Detection System Could Prevent Shoulder Injuries In Baseball Pitchers

    New IDSA Guidelines Aim To Reduce Death, Disability And Cost Of Prosthetic Joint Infections

    Biceps Tenodesis Hastens Recovery From Shoulder Injuries

    Previous 5 Features ...

    Next 5 Features ...

    More Features ...
    Related Multimedia

    Interview with Dr. Patel: Roles for arthroscopic surgery in osteoarthritis/hip resurfacing

    Interview with Dr. Patel: The Reasons for Back Pain and Diagnostic Methods

    Interview with Dr. Prodromos: High Tibial Osteotomy 1

    More Features ...
    Related Content
    U.S. to Reassess Arthritis Drug Safety

    FDA OKs New Rheumatoid Arthritis Drug

    Healthy Diet = Healthy Joints

    FDA Says Remicade Users Suffer Ailments

    Are Elderly Inhibited by Rheumatoid Arthritis

    More Features ...
    Home About Us Press Jobs Advertise With Us Contact Us
    © 2021 Body1 All rights reserved.
    Disclaimer: The information provided within this website is for educational purposes only and is not a substitute for consultation with your physician or healthcare provider. The opinions expressed herein are not necessarily those of the Owners and Sponsors of this site. By using this site you agree to indemnify, and hold the Owners and Sponsors harmless, from any disputes arising from content posted here-in.